TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN
US-2017145391-A1 · May 25, 2017 · US
This page is not indexed by search engines while we improve data quality.
Ludwig Inst Cancer Res — Physics
Ludwig Inst Cancer Res holds 3 patents in Physics, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Ludwig Inst Cancer Res |
| Technology | Physics |
| Patents in slice | 3 |
| Recent patents in slice | 0 |
| First year | 2015 |
| Last year | 2017 |
Representative patents
Notable publications linking Ludwig Inst Cancer Res to Physics.
TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN
US-2017145391-A1 · May 25, 2017 · US
In vivo efficacy of ny-eso-1 plus adjuvant
US-2016000894-A1 · Jan 7, 2016 · US
In vivo efficacy of ny-eso-1 plus adjuvant
US-2016000894-A1 · Jan 7, 2016 · US
In vivo efficacy of ny-eso-1 plus adjuvant
US-2016000894-A1 · Jan 7, 2016 · US
Recent filings
Latest patents from Ludwig Inst Cancer Res in Physics.
TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN
US-2017145391-A1 · May 25, 2017 · US
TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (mTOR) PROTEIN
US-2017145391-A1 · May 25, 2017 · US
In vivo efficacy of ny-eso-1 plus adjuvant
US-2016000894-A1 · Jan 7, 2016 · US
In vivo efficacy of ny-eso-1 plus adjuvant
US-2016000894-A1 · Jan 7, 2016 · US
In vivo efficacy of ny-eso-1 plus adjuvant
US-2016000894-A1 · Jan 7, 2016 · US
Related pages
Navigate to parent entity pages.